Foley Hoag

Foley Hoag LLP is a prominent Boston-headquartered law firm with a national and international presence, maintaining offices in New York City, Washington, D.C., Denver, and Paris. As an AmLaw 200 firm, ranked #132 in 2025, it is a significant player in the legal landscape with over 300 lawyers globally. The firm is recognized for providing strategic legal services to public, private, and government clients across various sectors.

The firm's intellectual property litigation practice specializes in high-stakes disputes, particularly in the life sciences, technology, energy, climate, and cannabis sectors. Foley Hoag is well-versed in complex Abbreviated New Drug Application (ANDA) litigations under the Hatch-Waxman Act and disputes combining patent, contract, and trade secret rights. The IP team includes numerous attorneys and technical specialists with Ph.D.s in life sciences fields, enabling deep technical expertise.

Foley Hoag primarily represents defendants in patent litigation, with all five tracked case appearances being on the defense side. The firm is known for effectively defending operating companies, frequently litigating against leading firms and securing significant victories. Their litigation department is adept at handling "bet the company" patent litigation across federal and state courts, as well as administrative tribunals.

Notable representations include defending Regeneron Pharmaceuticals, Inc. in an aflibercept biosimilar dispute, which settled in February 2026, following the Patent Trial and Appeal Board's denial of institution for two inter partes review (IPR) petitions challenging Regeneron's patents. In Sun Pharmaceutical Industries, Inc. v. Biofrontera Inc., Foley Hoag successfully represented Biofrontera as defendant, securing a Final Written Decision from the U.S. Patent Trial and Appeal Board (PTAB) in February 2026, which found all challenged claims of one of Sun Pharma's patents unpatentable.

The firm possesses a robust PTAB/IPR practice, with Peter A. Sullivan co-chairing the Patent Trial and Appeal Board practice group. They are active in defending clients in PTAB proceedings, particularly within the life sciences and technology industries. Key partners in the IP litigation practice include Peter A. Sullivan, David P. Halstead (who co-chairs the Intellectual Property department and holds a Ph.D. in Organic Chemistry), and Stephen Kenny. Jeffrey I.D. Lewis and Adam L. Perlman are also prominent attorneys involved in the firm's patent litigation matters.